What Is Apolipoprotein B and Why Does It Matter?

What Is Apolipoprotein B?

Apolipoprotein B (ApoB) and LDL cholesterol are both related to cardiovascular risk, but they measure different aspects of lipid metabolism. ApoB measures the number of atherogenic lipoprotein particles (e.g., LDL and VLDL), while LDL represents the cholesterol content within LDL particles. This distinction is critical because ApoB provides a more accurate assessment of the number of atherogenic particles. Atherogenic lipoprotein particles contribute to atherosclerosis (narrowing of the coronary arteries) and cardiac events (such as heart attacks or angina).

The Importance of LDL Cholesterol

In roughly 1 in 5 patients, ApoB and LDL levels are discordant (e.g., high ApoB with normal LDL). This is particularly common in individuals with obesity, diabetes, or metabolic syndrome. Studies show that high ApoB, even with low LDL, is linked to increased cardiovascular events, arterial stiffness, and carotid plaque formation (a cause of strokes). Additionally, ApoB better predicts risk in statin-treated patients or those with normal LDL.

How ApoB Impacts Cardiovascular Health

LDL remains the primary guideline-recommended marker but may underestimate risk in discordant cases, where patients may benefit from intensified lipid-lowering therapy.

The Future of Cardiovascular Risk Assessment

In summary, while LDL remains widely used, ApoB offers a more precise measure of atherogenic particle burden, helping clinicians identify and manage high-risk patients more effectively.

Dr Tim Trodd

Family Medicine, Functional Medicine, General Practice

MBBS (London)
DCH (London)
DRCOG (UK)
MRCGP (UK)
FHKAM (Family Medicine)

View Profile View Reports & Publications

Health Articles by Dr Tim Trodd

Interviews

References

Johannesen, C.D.L., Mortensen, M.B., Langsted, A. and Nordestgaard, B.G. (2021) 'Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients', Journal of the American College of Cardiology, 77(11), pp. 1439–1450. Available at: https://www.jacc.org/doi/10.1016/j.jacc.2021.01.027
Sniderman, A.D., Williams, K., Contois, J.H., Monroe, H.M., McQueen, M.J., de Graaf, J. and Furberg, C.D. (2011) 'A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk', Circulation: Cardiovascular Quality and Outcomes, 4(3), pp. 337–345. Available at: https://www.ahajournals.org/doi/10.1161/circoutcomes.110.959247
Wilkins, J.T., Li, R.C., Sniderman, A., Chan, C. and Lloyd-Jones, D.M. (2016) 'Discordance between apolipoprotein B and LDL-cholesterol in young adults predicts coronary artery calcification: the CARDIA study', Journal of the American College of Cardiology, 67(2), pp. 193–201. Available at: https://www.jacc.org/doi/10.1016/j.jacc.2015.10.055